Gliknik pursues several approaches to immune modulation for patients with cancer or autoimmune disease. Much attention has been paid to our stradomer™ approach.

Stradomers™ come in a wide variety of shapes and sizes. Each one presents multiple immunoglobulin Fc to some or all of its many ligands and receptors simultaneously.  GL-2045 is the first of our general stradomers™, a multimerized cluster stradomer™ that binds avidly to a wide range of receptors and ligands to which immunoglobulin IgG1 Fc normally has affinity. It is being developed as a recombinant mimetic of the pooled human blood product IVIG for autoimmunity. GL-0719 is another example. It preferentially binds complement C1q better than Fc receptors, making it a complement-preferential stradomer™. Gliknik also has generated stradomers™ that preferentially bind FcγRI, FcγRIIb, FcRn, or that preferentially binds Fc receptors preferentially over complement C1q.

Depending on the purpose, Gliknik stradomers™ are comprised of mutated or non-mutated IgG1, IgG4, or IgG3. They may be cluster, serial, or core in structure. They may also be combinations of various immunoglobulin components and structures.